Confidential Treatment Requested Under 17 C.F.R. 200.80(b)(4) and 240-24b-2 Statement of Work To the Agreement between RADIUS HEALTH, INC. (RADIUS) and LONZA Sales AG dated 16 of October 2007 Supplemental analytical services Number RDS-001-SC005 Product Code/Name RDS-001 Abaloparatide Description of the proposed change: Manufacturing of an RS solution and supply of 60 extra vials to Vetter. These vials will be produced together with the 60 vials already ordered (PO# 03329) Price Agreed [*] Radius Name: Naveen Palwai Signature: /s/ Naveen Palwai Date : 17 Mar 2016 Radius Name: Wajiha Khan Signature: /s/ Wajiha Khan Date : March 17, 2016 Lonza Sales AG Name : Paul Tastenhoye Signature : /s/ Paul Tastenhoye Date: 17/03/2016 Lonza Sales AG Name : Frederique Mutterer Signature : /s/ Frederique Mutterer Date : 17/03/2016

Exhibit 10.3

Confidential Treatment Requested Under 17 C.F.R. §§ 200.80(b)(4) and 240-24b-2

Statement of Work

To the Agreement between RADIUS HEALTH, INC. (“RADIUS”) and LONZA Sales AG dated 16 of October 2007

Supplemental analytical services

Additional notes: /

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

1

Confidential Treatment Requested Under 17 C.F.R. §§ 200.80(b)(4) and 240-24b-2

Detailed description of the proposed change

Manufacturing of an RS solution and supply of 60 extra vials to Vetter. These vials will be produced together with the 60 vials already ordered (PO# 03329)

Timescale

By mid-May.

Price and Terms of Payment

1.      Price

·                  [*]€

2.      Payment

100% upon completion

oooOOOooo

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

2